In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) reported that Highbridge Capital Management has picked up 229,419 of common stock as of 2017-07-31.
The acquisition brings the aggregate amount owned by Highbridge Capital Management to a total of 229,419 representing a 2.06% in the company.
For those not familiar with the company, Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
A glance at Pernix Therapeutics Holdings Inc. (NASDAQ:PTX)’s key stats reveals a current market capitalization of 33.35M based on 11.12M shares outstanding and a price at last close of $3.00 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2015-08-19, Siegel picked up 5,000 at a purchase price of $4.49 per share.This brings their total holding to 5,000 as of the date of the filing.
On the sell side, the most recent transaction saw Clifford unload 2,246 shares at a sale price of $10.00. This brings their total holding to 7,506.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.